I’m excited to share a more detailed look into my professional journey and the work I’ve been fortunate to lead at the intersection of AI, data science, and drug discovery. Over the years, I’ve focused on building data-driven strategies and platforms that help translate complex biological data into meaningful therapeutic impact. I’m grateful for the opportunity to collaborate with incredible teams and contribute to innovation in biotech. Here is my biography.

After nearly two decades at the intersection of science, strategy, and innovation, I've had the privilege of building and leading teams that transform how healthcare organizations use data and technology to deliver more equitable, efficient, and impactful care. I'm proud to share my professional biography that captures this journey.

Ross Bundy is a pioneering biotechnology leader driving innovation in biosensor technology and genome editing optimization. As the CEO of CRISPR QC and co-founder of Cardea Bio Inc., he has been instrumental in developing platforms that enable real-time biological insights through the "Internet of Biology." With expertise in business development, financial strategy, and operational management, Bundy has successfully scaled multiple companies and forged key industry partnerships. His visionary leadership and strategic execution continue to shape the future of biotechnology, advancing diagnostics, therapeutics, and bioinformatics with cutting-edge solutions.

Deb Kelly is a pioneering leader in biomedical research, known for her expertise in molecular biophysics, computational modeling, and high-resolution imaging to advance translational medicine. As Executive Director of Structural Oncology LLC and a professor at Penn State University, she has led groundbreaking research in cancer and viral health threats, integrating artificial intelligence and bioinformatics to drive drug discovery and clinical decision-making. With over 15 years of experience managing multidisciplinary teams, securing millions in research funding, and mentoring early-career professionals, Kelly’s work has had a lasting impact on biomedical science. Her strategic leadership, innovative research, and commitment to mentorship continue to shape the future of medical advancements and therapeutic development.

Gadareth Higgs is an experienced independent consultant specializing in startup and life science strategy, with over 15 years of postgraduate expertise. He combines a strong foundation in molecular biology and bioinformatics with a proven track record in business development, AI strategy, data analysis, and operational leadership. As the Principal at Higgs Insights, LLC, he delivers actionable insights and transformative strategies to startups and large organizations alike. Gadareth has led impactful initiatives in precision oncology, healthcare consulting, and business transformations, leveraging his expertise to optimize operations, secure strategic partnerships, and drive growth. His ability to synthesize complex data, develop innovative solutions, and communicate effectively has made him a trusted advisor to clients across the healthcare and life sciences sectors.

Raymond Chang is a seasoned Translational Imaging Scientist with over two decades of experience spanning pharmaceutical research, contract research organizations, and academic discovery. Renowned for his expertise in advanced imaging modalities such as PET, SPECT, and CT, Chang has contributed significantly to the development of preclinical disease models and innovative therapeutics. His career highlights include leading the enterprise implementation of multimodality bioinformatics systems, developing cutting-edge imaging tools, and managing GLP and Non-GLP studies that bridge preclinical and clinical research. A dedicated leader and collaborator, Chang excels in regulatory compliance, experimental design, and fostering partnerships, making him a pivotal figure in advancing personalized medicine and imaging science.